Trametinib and Nivolumab for glioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Dec 2024: Trial registered, NCT06712875
  2. 1 Apr 2025: Trial started, NCT06712875

The trials

NCT06712875: MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

State
Under way
Phase
Phase 1 and Phase 2
People
27 planned
Started
1 Apr 2025
Primary completion
Dec 2028
Arms
Trametinib combined with nivolumab (Cohort A)
Results
None posted
  1. 2 Dec 2024: Trial registered
  2. 1 Apr 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.